A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Summary: Aim: To determine efficacy and safety of intravenous micafungin vs. intravenous fluconazole in the treatment of oesophageal candidiasis. Methods: A total of 523 patients ≥16 years with documented oesophageal candidiasis were randomized (1:1) in this controlled, non‐inferiority study to receive either micafungin (150 mg/day) or fluconazole (200 mg/day). Response was evaluated clinically and endoscopically. Post‐treatment assessments were performed at 2 and 4 weeks after discontinuation of therapy. Results: Median duration of therapy was 14 days. For the primary end‐point of endoscopic cure, treatment difference was −0.3% (micafungin 87.7%, fluconazole 88.0%). Documented persistent invasive disease at the end of therapy was reported in 2.7% and 3.9% of patients, respectively. Both 84.8% of micafungin and 88.7% of fluconazole patients remained recurrence free at 4‐weeks post‐treatment. The overall therapeutic response rate was 87.3% for micafungin and 87.2% for fluconazole. The incidence of drug‐related adverse events was 27.7% for micafungin and 21.3% for fluconazole. Six (2.3%) micafungin‐ and two (0.8%) fluconazole‐treated patients discontinued therapy; rash was the most common event leading to discontinuation. Conclusion: Intravenous micafungin (150 mg daily) is well tolerated and as efficacious as intravenous fluconazole (200 mg daily) in the primary treatment of oesophageal candidiasis, achieving high rates of clinical and endoscopic cure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Ikeda, F., Wakai, Y., Matsumoto, S., Maki, K., Watabe, E., Tawara, S., Goto, T., Watanabe, Y., Matsumoto, F., & Kuwahara, S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.614-618.2000 · Cited by 147
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Kuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60605-9 · Cited by 692
Echinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
“caspofungin, micafungin or anidulafungin) to that of fluconazole for oesophageal candidiasis;([160-162]) the clinical responses to the study echinocandin and fluconazole were similar.”
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
Denning, D. W., Marr, K. A., Lau, W. M., Facklam, D. P., Ratanatharathorn, V., Becker, C., Ullmann, A. J., Seibel, N. L., Flynn, P. M., van Burik, J.-A. H., et al. (2006) · Journal of Infection · doi:10.1016/j.jinf.2006.03.003 · Cited by 294
Self-citation
Metadata
- Authors
- De Wet, N. T. E., Bester, A. J., Viljoen, J. J., Filho, F., Suleiman, J. M., Ticona, E., Llanos, E. A., Fisco, C., Lau, W., & Buell, D.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2005-03-24
- Volume
- 21
- Issue
- 7
- Pages
- 899-907
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2015624703
- Cited by
- 145
- References
- 3
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. https://app.cochat.ai/papers/10.1111/j.1365-2036.2005.02427.x
- The paper
- De Wet, N. T. E., Bester, A. J., Viljoen, J. J., Filho, F., Suleiman, J. M., Ticona, E., Llanos, E. A., Fisco, C., Lau, W., & Buell, D. (2005). A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2005.02427.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.